Maravai LifeSciences Holdings, Inc. $MRVI Shares Sold by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. lessened its stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 12.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,414,872 shares of the company’s stock after selling 197,969 shares during the quarter. Goldman Sachs Group Inc. owned about 0.56% of Maravai LifeSciences worth $3,127,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. McAdam LLC purchased a new position in Maravai LifeSciences during the 1st quarter worth approximately $31,000. EntryPoint Capital LLC acquired a new stake in shares of Maravai LifeSciences in the 1st quarter valued at $32,000. Teacher Retirement System of Texas acquired a new stake in shares of Maravai LifeSciences in the 1st quarter valued at $37,000. Aigen Investment Management LP acquired a new stake in shares of Maravai LifeSciences in the 1st quarter valued at $37,000. Finally, Performa Ltd US LLC lifted its stake in shares of Maravai LifeSciences by 245.0% in the 1st quarter. Performa Ltd US LLC now owns 17,250 shares of the company’s stock valued at $38,000 after purchasing an additional 12,250 shares during the last quarter. Institutional investors and hedge funds own 50.25% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Royal Bank Of Canada reduced their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “outperform” rating for the company in a research note on Tuesday, August 12th. Three equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Maravai LifeSciences currently has a consensus rating of “Hold” and an average target price of $5.22.

Maravai LifeSciences Stock Performance

NASDAQ:MRVI opened at $2.70 on Friday. The firm’s 50-day moving average is $2.50 and its 200-day moving average is $2.32. Maravai LifeSciences Holdings, Inc. has a 52-week low of $1.66 and a 52-week high of $8.99. The company has a debt-to-equity ratio of 0.68, a quick ratio of 4.49 and a current ratio of 5.16. The company has a market cap of $689.47 million, a price-to-earnings ratio of -1.99 and a beta of 0.29.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.